Literature DB >> 10618417

Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone.

M L Wong1, M A Kling, P J Munson, S Listwak, J Licinio, P Prolo, B Karp, I E McCutcheon, T D Geracioti, M D DeBellis, K C Rice, D S Goldstein, J D Veldhuis, G P Chrousos, E H Oldfield, S M McCann, P W Gold.   

Abstract

Both stress-system activation and melancholic depression are characterized by fear, constricted affect, stereotyped thinking, and similar changes in autonomic and neuroendocrine function. Because norepinephrine (NE) and corticotropin-releasing hormone (CRH) can produce these physiological and behavioral changes, we measured the cerebrospinal fluid (CSF) levels each hour for 30 consecutive hours in controls and in patients with melancholic depression. Plasma adrenocorticotropic hormone (ACTH) and cortisol levels were obtained every 30 min. Depressed patients had significantly higher CSF NE and plasma cortisol levels that were increased around the clock. Diurnal variations in CSF NE and plasma cortisol levels were virtually superimposable and positively correlated with each other in both patients and controls. Despite their hypercortisolism, depressed patients had normal levels of plasma ACTH and CSF CRH. However, plasma ACTH and CSF CRH levels in depressed patients were inappropriately high, considering the degree of their hypercortisolism. In contrast to the significant negative correlation between plasma cortisol and CSF CRH levels seen in controls, patients with depression showed no statistical relationship between these parameters. These data indicate that persistent stress-system dysfunction in melancholic depression is independent of the conscious stress of the disorder. These data also suggest mutually reinforcing bidirectional links between a central hypernoradrenergic state and the hyperfunctioning of specific central CRH pathways that each are driven and sustained by hypercortisolism. We postulate that alpha-noradrenergic blockade, CRH antagonists, and treatment with antiglucocorticoids may act at different loci, alone or in combination, in the treatment of major depression with melancholic features.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10618417      PMCID: PMC26662          DOI: 10.1073/pnas.97.1.325

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  44 in total

1.  A rating scale for depression.

Authors:  M HAMILTON
Journal:  J Neurol Neurosurg Psychiatry       Date:  1960-02       Impact factor: 10.154

2.  Release of galanin from isolated perfused porcine adrenal glands: role of splanchnic nerves.

Authors:  J J Holst; M Ehrhart-Bornstein; T Messell; S S Poulsen; H Harling
Journal:  Am J Physiol       Date:  1991-07

3.  Urinary free cortisol excretion in depression.

Authors:  B J Carroll; G C Curtis; B M Davies; J Mendels; A A Sugerman
Journal:  Psychol Med       Date:  1976-02       Impact factor: 7.723

4.  Plasma and cerebrospinal fluid neurochemical pattern in Menkes disease.

Authors:  S G Kaler; D S Goldstein; C Holmes; J A Salerno; W A Gahl
Journal:  Ann Neurol       Date:  1993-02       Impact factor: 10.422

5.  Sympathoadrenal regulation of adrenal androstenedione release.

Authors:  M Ehrhart-Bornstein; S R Bornstein; H Güse-Behling; H G Stromeyer; T N Rasmussen; W A Scherbaum; G Adler; J J Holst
Journal:  Neuroendocrinology       Date:  1994-04       Impact factor: 4.914

6.  Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey.

Authors:  R C Kessler; K A McGonagle; S Zhao; C B Nelson; M Hughes; S Eshleman; H U Wittchen; K S Kendler
Journal:  Arch Gen Psychiatry       Date:  1994-01

Review 7.  Catecholamines in depression: an update.

Authors:  W Z Potter; H K Manji
Journal:  Clin Chem       Date:  1994-02       Impact factor: 8.327

8.  Diurnal variation of cerebrospinal fluid immunoreactive corticotropin-releasing hormone levels in healthy volunteers.

Authors:  M A Kling; M D DeBellis; D K O'Rourke; S J Listwak; T D Geracioti; I E McCutcheon; K T Kalogeras; E H Oldfield; P W Gold
Journal:  J Clin Endocrinol Metab       Date:  1994-07       Impact factor: 5.958

9.  Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients.

Authors:  F C Raadsheer; W J Hoogendijk; F C Stam; F J Tilders; D F Swaab
Journal:  Neuroendocrinology       Date:  1994-10       Impact factor: 4.914

10.  Corticosterone effects on corticotropin-releasing hormone mRNA in the central nucleus of the amygdala and the parvocellular region of the paraventricular nucleus of the hypothalamus.

Authors:  S Makino; P W Gold; J Schulkin
Journal:  Brain Res       Date:  1994-03-21       Impact factor: 3.252

View more
  149 in total

1.  Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates.

Authors:  K E Habib; K P Weld; K C Rice; J Pushkas; M Champoux; S Listwak; E L Webster; A J Atkinson; J Schulkin; C Contoreggi; G P Chrousos; S M McCann; S J Suomi; J D Higley; P W Gold
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

Review 2.  Cannabinoid modulation of noradrenergic circuits: implications for psychiatric disorders.

Authors:  Ana Franky Carvalho; Elisabeth J Van Bockstaele
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-01-24       Impact factor: 5.067

Review 3.  Insulin resistance, obesity, inflammation, and depression in polycystic ovary syndrome: biobehavioral mechanisms and interventions.

Authors:  Kristen Farrell; Michael H Antoni
Journal:  Fertil Steril       Date:  2010-05-14       Impact factor: 7.329

Review 4.  Neurobiology of chronic mild stress: parallels to major depression.

Authors:  Matthew N Hill; Kim G C Hellemans; Pamela Verma; Boris B Gorzalka; Joanne Weinberg
Journal:  Neurosci Biobehav Rev       Date:  2012-07-07       Impact factor: 8.989

5.  Social supports and serotonin transporter gene moderate depression in maltreated children.

Authors:  Joan Kaufman; Bao-Zhu Yang; Heather Douglas-Palumberi; Shadi Houshyar; Deborah Lipschitz; John H Krystal; Joel Gelernter
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-24       Impact factor: 11.205

6.  Stress triggered changes in gene expression in adrenal medulla: transcriptional responses to acute and chronic stress.

Authors:  Esther L Sabban; Xiaoping Liu; Lidia Serova; Volodia Gueorguiev; Richard Kvetnansky
Journal:  Cell Mol Neurobiol       Date:  2006-05-12       Impact factor: 5.046

7.  Influence of chronic administration of antidepressant drugs on mRNA for galanin, galanin receptors, and tyrosine hydroxylase in catecholaminergic and serotonergic cell-body regions in rat brain.

Authors:  Molly L Rovin; Katherine A Boss-Williams; Reid S Alisch; James C Ritchie; David Weinshenker; Charles H K West; Jay M Weiss
Journal:  Neuropeptides       Date:  2012-02-10       Impact factor: 3.286

8.  Chronic stress and obesity: a new view of "comfort food".

Authors:  Mary F Dallman; Norman Pecoraro; Susan F Akana; Susanne E La Fleur; Francisca Gomez; Hani Houshyar; M E Bell; Seema Bhatnagar; Kevin D Laugero; Sotara Manalo
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-15       Impact factor: 11.205

Review 9.  Drug discovery strategies that focus on the endocannabinoid signaling system in psychiatric disease.

Authors:  Ryan Wyrofsky; Paul McGonigle; Elisabeth J Van Bockstaele
Journal:  Expert Opin Drug Discov       Date:  2014-12-09       Impact factor: 6.098

Review 10.  The organization of the stress system and its dysregulation in depressive illness.

Authors:  P W Gold
Journal:  Mol Psychiatry       Date:  2014-12-09       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.